Betahistine Hydrochloride

盐酸倍他司汀

Report date: 2022/02/21 15:49:30
NME

Base Information

Drug NameBetahistine Hydrochloride
Drug Alias Namebetahistinum盐酸甲胺乙吡啶betahistinaSercHistalean +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistamine receptor antagonists
TargetsHistamine receptor
Therapy Area/IndicationsBipolar II DisorderBipolar I DisorderSchizophrenia +[16] 
Global Approved IndicationsArteriosclerosisCerebrovascular DisordersVertigo +[5] 
Approved Indications in ChinaArteriosclerosisCerebrovascular DisordersVertigo +[4] 
Original Approved Country/TerritoryUnited States
Original Approved Date1966/01/01
Country/TerritoryBelgiumUnited StatesEurope +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesAuris Medical AgWuhan Jiu'An Pharmaceutical Co Ltd
Inactive CompaniesEunice Kennedy Shriver National Institute Of Child Health And Human DevelopmentNathan Kline Institute For Psychiatric ResearchObecure Ltd +[5] 
Active IndicationsArteriosclerosisCerebrovascular DisordersVertigo +[5] 
Inactive IndicationsBipolar II DisorderBipolar I DisorderSchizophrenia +[11] 

Other Information

ATC CodeN07CA01
Related LinksWikipediaDrugBankKEGG